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Abstract
Introduction: Parkinson’s disease (PD) and multiple system atrophy (MSA) are neurodegenerative diseases that are
characterized by the intracellular accumulation of alpha-synuclein containing aggregates. Recent increasing
evidence suggests that Parkinson’s disease and MSA pathology spread throughout the nervous system in a
spatiotemporal fashion, possibly by prion-like propagation of alpha-synuclein positive aggregates between
synaptically connected areas. Concurrently, intracerebral injection of pathological alpha-synuclein into transgenic
mice overexpressing human wild-type alpha-synuclein, or human alpha-synuclein with the familial A53T mutation,
or into wild-type mice
causes spreading of alpha-synuclein pathology in the CNS. Considering that wild-type mice naturally also express
a threonine at codon 53 of alpha-synuclein, it has remained unclear whether human wild-type alpha-synuclein
alone, in the absence of endogenously expressed mouse alpha-synuclein, would support a similar propagation of
alpha-synuclein pathology in vivo.
Results: Here we show that brain extracts from two patients with MSA and two patients with probable incidental
Lewy body disease (iLBD) but not phosphate-buffered saline induce prion-like spreading of pathological alpha-
synuclein after intrastriatal injection into mice expressing human wild-type alpha-synuclein. Mice were sacrificed at
3, 6, and 9 months post injection and analyzed neuropathologically and biochemically.
Mice injected with brain extracts from patients with MSA or probable iLBD both accumulated intraneuronal
inclusion bodies, which stained positive for phosphorylated alpha-synuclein and appeared predominantly within
the injected brain hemisphere after 6 months. After 9 months these intraneuronal inclusion bodies had spread to
the contralateral hemisphere and more rostral and caudal areas. Biochemical analysis showed that brains of
mice injected with brain extracts from patients with MSA and probable iLBD contained hyperphosphorylated
alpha-synuclein that also seeded aggregation of recombinant human wild-type alpha-synuclein in a Thioflavin T
binding assay.
Conclusions: Our results indicate that human wild-type alpha-synuclein supports the prion-like spreading of
alpha-synuclein pathology in the absence of endogenously expressed mouse alpha-synuclein in vivo.
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Introduction
Parkinson’s disease (PD), multiple system atrophy (MSA),
and dementia with Lewy bodies (DLB) are part of a
spectrum of neurodegenerative disorders characterized by
accumulation of misfolded alpha-synuclein, preferentially
in cells of the nervous system, and are therefore often
conceptualized as synucleinopathies [52, 53, 60]. Missense
mutations in alpha-synuclein, such as A53T, or duplica-
tions and triplications of the SNCA gene encoding alpha-
synuclein have been linked to familial PD and suggest that
in synucleinopathies alpha-synuclein itself can become
pathogenic [4, 15, 20, 37, 51, 62]. This has also raised
interest in the putative relationship between posttransla-
tional modifications of alpha-synuclein, such as hyperpho-
sphorylation at S129, and its misfolding and deposition in
disease [11, 49].
The seminal neuropathological analyses of Braak and
co-workers suggest that the regional distribution of
pathological alpha-synuclein in the brains of patients is
progressive and can be classified into stages [3, 27]. Al-
though this concept is not undisputed [35], aggregation of
alpha-synuclein in embryonic dopamine neurons grafted
into the striatum of PD patients for therapy spurred the
hypothesis that misfolded alpha-synuclein may indeed
spread between cells and seed aggregation of normal
alpha-synuclein [17, 25]. Subsequent studies in cultured
neurons and rodents showed that exogenous pathological
alpha-synuclein can seed misfolding and aggregation of na-
tive alpha-synuclein and that pathological alpha-synuclein
may propagate in a prion-like manner within the nervous
system [8, 18, 24, 28, 29, 31, 33, 41, 42, 47, 58, 59, 61]. In
most of the above studies either synthetic alpha-synuclein
fibrils generated in vitro or transgenic M83-mice overex-
pressing alpha-synuclein with the familial A53T mutation,
or wild-type mice or rats naturally expressing a threonine
at codon 53 were used for inoculation experiments. While
propagation of alpha-synuclein pathology can also be
induced in M20-mice overexpressing human wild-type
alpha-synuclein in the presence of endogenously expressed
mouse alpha-synuclein [45, 46], it remains unresolved
whether human wild-type alpha-synuclein by itself, in the
absence of endogenously expressed mouse alpha-synuclein,
would support prion-like spreading of pathological alpha-
synuclein in mice. Moreover, it is unresolved whether
endogenously expressed mouse alpha-synuclein may
actually hamper misfolding and spreading of transge-
nically expressed human alpha-synuclein. In the field
of prion diseases, transgenic mice expressing human
prion protein in the presence of endogenously expressed
mouse prion protein are resistant to infection with human
prions from Creutzfeldt-Jakob disease patients, and only
become susceptible to human prions when endogenous
expression of the mouse prion protein is ablated [56, 57].
We therefore investigated the fate of mice expressing hu-
man wild-type alpha-synuclein on a knockout background
for mouse alpha-synuclein after intrastriatal injection of
brain extracts from patients with MSA and probable
incidental Lewy body disease (iLBD) [14, 21]. Our results
suggest that human wild-type alpha-synuclein indeed
supports prion-like propagation of pathological alpha-
synuclein from the brains of MSA patients. Moreover,
our results suggest that not only MSA brains but also
brains of individuals with iLBD contain misfolded alpha-
synuclein species that can induce prion-like spreading of
misfolded alpha-synuclein in mice.
Materials and methods
Preparation of brain extracts for injections
Insoluble fractions from human cerebral cortices were
prepared as previously described [31]. Briefly, 0.2 g of
frozen cortical brain tissue from two MSA and two
probable iLBD cases (Table 1) each were homogenized
in 18 volumes of Buffer A [10 mM Tris–HCl, pH 7.4,
0.8 M NaCl, 1 mM EGTA, 10 % sucrose, with protease
and phosphatase inhibitors (cOmplete and PhosStop,
Roche Diagnostics)] by three 60 s cycles in a Precellys
24-Dual homogenizer (Peqlab). Sarkosyl was added to
the homogenate at a final concentration of 2 %. The
mixture was incubated for 30 min at 37 °C, sonicated,
and spun at 9,100 × g for 10 min. The supernatant was
further centrifuged at 100,000 × g for 30 min at 25 °C.
The sarkosyl-insoluble pellet was taken up in 540 μl of
Ca2+- and Mg2+-free PBS (pH 7.4) and used for stereotaxic
injections. The concentration of alpha-synuclein in
sarkosyl-insoluble fractions was measured with the Senso-
lyte anti-alpha-synuclein ELISA kit (Anaspec) according
to the manufacturer’s directions. Briefly, sarkosyl in-
soluble fractions were diluted in the buffer provided
Table 1 Characteristics of MSA and iLBD cases used for inoculation experiments
Case ID Sex (M/F) Age at death (years) Postmortem delay time (h) Neurological diagnosis Alpha-synuclein concentration in the
sarkosyl-insoluble fraction (ng/ml)
Source
MSA1 F 51 48 MSA 20.99 BBCT
MSA2 M 59 32 MSA 21.52 QSBB
iLBD1 M 78 48 non-clinical 18.05 BBCM
iLBD2 F 68 48 non-clinical 8.17 BBCL
MSA multiple system atrophy, iLBD incidental Lewy body disease, M male, F female, BBCT Brain Banking Center Tübingen, QSBB Queen Square Brain Bank for
Neurological Disorders, BBCM Brain Banking Center Münster, BBCL Brain Banking Center Leipzig
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and incubated in precoated wells overnight at 4 °C. The
wells were washed seven times with the provided wash
buffer. After a final wash, the color was developed using
the TMB-ELISA substrate provided. Optical densities
were measured at 450 nm with a Fluostar Omega micro-
plate reader (BMG Labtech).
Stereotaxic surgery
Six- to eight-week-old FVB;129S6-Sncatm1NbmTg(SN-
CA)1Nbm/J mice (short: Tg(SNCA)1Nbm/J mice, The
Jackson Laboratory) were anaesthetized with isoflurane
and stereotaxically injected with 30 μl of cortical brain
extract from MSA or probable iLBD cases or PBS into
the left striatum (coordinates: +0.2 mm relative to the
bregma, +2.0 mm relative to the midline, 2.6 mm below
the dura) using a 27-gauge disposable hypodermic syringe.
After recovery from surgery, animals were monitored daily
for health and three times weekly for signs of neurologic
illness such as reduced grooming, ataxia, tremor, bradyki-
nesia, akinesia, lethargy, circling, tail rigidity, paraparesis,
paralysis, kyphosis, and more. At 3, 6, and 9 months post
injection the mice were sacrificed by overdose with keta-
mine/xylazine and then transcardially perfused with 0.9 %
saline followed by 10 % formalin neutral buffer solution
(Sigma). Brains were fixed overnight with 1 % formalin
neutral buffer solution for immunohistochemistry. For
biochemical analysis, brains were snap-frozen on dry ice
and stored at −80 °C. All animal studies were approved by
the animal protection committee of the North Rhine-
Westphalia State Environment Agency (LANUV).
Immunohistochemical analysis
For paraffin sections brains fixed in 1 % formalin were
dehydrated and infiltrated with paraffin using standard pro-
cedures. Brains were cut into 8-μm-thick coronal sections,
mounted on glass slides, deparaffinized, and hydrated
through a series of graded ethanol solutions followed by
antigen-retrieval treatment for 10 min (Additional file 1).
Endogenous tissue peroxide was inhibited by incubating
slides in 3 % hydrogen peroxide solution for 30 min. Slides
were then blocked with 30 % (v/v) normal goat serum, 1 %
(v/v) bovine serum albumin, and 0.5 % Triton X-100 for
1 h and then incubated with primary antibody overnight at
4 °C (Additional file 1). Bound antibody was detected using
a Vectastain ABC kit (Vector Laboratories) and visualized
using DAB (3-3’-diaminobenzidine). Slides were counter-
stained with Hematoxylin QS (Vector Laboratories) and
coverslipped with Vectamount AQ (Vector Laboratories).
All slides were scanned using an Axio Scan.Z1 scanner and
ZEN lite software (Carl Zeiss). For cryosections brains were
fixed in 4 % formalin and protected in 30 % sucrose solu-
tion in PBS using standard procedures. Brains were cut into
25-μm-thick coronal sections, followed by antigen-retrieval
treatment (Additional file 1). Staining was performed on
free-floating sections. Brain sections were blocked with
10 % (v/v) normal goat serum and 0.3 % Triton X-100 for
1 h and incubated with primary antibody overnight as
above. Bound antibody was detected using a Liquid DAB+
Substrate Chromagen System (Dako). The sections were
mounted on slides, counterstained, coverslipped, and ana-
lyzed as above.
Immunofluorescence analysis
Paraffin-embedded tissues were cut into 8-μm-thick cor-
onal sections, deparaffinized, and hydrated followed by
antigen retrieval treatment for 10 min (Additional file 1).
The tissues were incubated in 1 mM CuSO4 in 50 mM
ammonium acetate buffer at pH 5. Slides were blocked
with 30 % (v/v) normal goat serum, 1 % (v/v) BSA, and
0.5 % Triton X-100 for 1 h and then incubated with pri-
mary antibody overnight at 4 °C (Additional file 1). After
washing twice with PBS containing 0.25 % (v/v) Triton
X-100 and once with PBS, sections were incubated with
secondary antibodies conjugated to Alexa Fluor 488- or
Alexa Fluor 568-conjugated goat anti-mouse or rabbit anti-
bodies (Thermo Fisher Scientific). Sections were stained
with DAPI (4’,6-diamidino-2-phenylindole; Thermo Fisher
Scientific), coverslipped with Fluoromount (Sigma), and
visualized using an LSM700 confocal microscope (Carl
Zeiss).
Biochemical analysis
Mouse brains were fractionated as described above for the
preparation of human brain extracts for injections. How-
ever, the sarkosyl-soluble supernatant and the sarkosyl-
insoluble pellet were taken up in Ca2+- and Mg2+-free PBS
(pH 7.4) with protease and phosphatase inhibitors
(cOmplete and PhosSTOP, Roche Diagnostics) and benzo-
nase nuclease (Sigma) for the removal of nucleic acid. Pro-
tein concentrations were determined with the Pierce BCA
Protein Assay Kit (Thermo Fisher Scientific). Samples
were taken up in 1× NuPAGE loading buffer, boiled for
10 min, and then loaded onto 4-12 % NuPAGE gels
(Thermo Fisher Scientific). Insoluble fractions of human
brains were prepared as described above for injections.
However, the sarkosyl-insoluble pellet was taken up in
500 μl of 30 mM Tris–HCl (pH 7.4) and sonicated. A
mouse monoclonal anti-alpha-synuclein antibody (clone
42, BD Biosciences) was incubated at a 1:20 dilution with
50 μl of Dynabeads protein G slurry (Thermo Fisher Sci-
entific) for 30 min at room temperature. Diluted insoluble
fractions were incubated with the immune complex for
1 h at room temperature. The resultant pellet (P1) was
washed three times with wash buffer and eluted with 20 μl
of elution buffer and 10 μl of 4× loading buffer. The
supernatant was subjected to a second immunoprecipita-
tion step with a fresh immune complex overnight at 4 °C.
The resultant pellet was washed three times with wash
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buffer. Finally, immunoprecipitated alpha-synuclein was
eluted in 20 μl of elution buffer and 10 μl of 4× loading
buffer, combined with the first pellet (P1), and boiled for
10 min. Protein was resolved on 4-12 % NuPAGE gels.
SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel
electrophoresis) was performed using a MOPS buffer
system (Thermo Fisher Scientific), and gels were subse-
quently transferred to PVDF membranes using a wet blot-
ting system. Blots were then cross-linked with 0.4 % (v/v)
paraformaldehyde in PBS for 30 min. Membranes were
blocked for 1 h at room temperature with 5 % (w/v) bo-
vine serum albumin in Tris-buffered saline containing
0.05 % (v/v) Tween 20 and then incubated with pri-
mary antibody overnight at 4 °C (Additional file 1).
Blots were developed with IRDye 680- or IRDye 800-
conjugated goat anti-mouse or goat anti-rabbit sec-
ondary antibodies (LI-COR Biosciences), and imaged
with an Odyssey infrared imaging system (LI-COR
Biosciences).
Sequential extraction was performed as previously
described [61]. Briefly, 10 % (w/v) brain homogenates
prepared in Ca2+- and Mg2+-free PBS (pH 7.4) were
shifted to high-salt (HS) buffer by the addition of NaCl
to a final concentration of 750 mM and EDTA to a final
concentration of 5 mM. One hundred microliters of
brain homogenate in HS buffer were sonicated for 5 min
using a water-bath sonicator and then centrifuged at
100,000 × g for 30 min at 4 °C. The pellet was then re-
suspended by pipetting in 100 μl of HS-T buffer [50 mM
Tris–HCl (pH 7.5), 750 mM NaCl, 5 mM EDTA, 1 % (v/v)
Triton X-100]. Samples were then sonicated and centri-
fuged at 100,000 × g for 30 min at 4 °C. Cycles of extrac-
tion, sonication, and centrifugation were repeated using
the following buffers in sequence: RIPA buffer [50 mM
Tris–HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1 % (v/v)
Nonidet P-40, 0.5 % (w/v) sodium deoxycholate, 0.1 %
(w/v) SDS] and SDS buffer [50 mM Tris–HCl (pH 7.5),
2 % (w/v) SDS]. Protease and phosphatase inhibitors were
added to buffers before use. For each extraction step, a
60 μl sample of the supernatant was removed, adjusted to
1× NuPAGE loading buffer by the addition of 20 μl of 4×
loading buffer and then boiled. Samples from each of the
extraction steps were analyzed by immunoblotting as de-
scribed before.
To determine alpha-synuclein expression in different
brain regions of non-transgenic and Tg(SNCA)1Nbm/J
mice, tissue from these regions was collected and ho-
mogenized in Ca2+- and Mg2+-free PBS (pH 7.4) to yield
a 10 % (w/v) homogenate to which sarkosyl was added
to yield a final concentration of 2 % (v/v) sarkosyl. Pro-
tein concentrations were determined using the Pierce
BCA Protein Assay Kit, and samples of 5 μg total protein
were separated on 4-12 % NuPAGE gels as described
above.
Production and purification of recombinant alpha-synuclein
Alpha-synuclein cDNA was transferred from plasmid
pMA-T-SCNA (Thermo Fisher Scientific) as an NheI-
XhoI fragment into the expression plasmid pET28a(+)
(Merck) yielding pET28a(+)-aSWT. The E. coli strain
BL21(DE3) (Merck) was transformed with sequence
verified pET28a(+)-aSWT and individual clones were
screened for production of recombinant protein follow-
ing induction with isopropyl-D-thiogalactopyranoside
(IPTG, Sigma). Expression with this system leads to
translocation of the 6His-alpha synuclein wild-type pro-
tein into the periplasmatic space. For protein produc-
tion, E. coli cells were grown at 37 °C in 1 L LB media
containing ampicillin and 1 % glucose to an OD600 of
approximately 0.5, induced with 1 mM IPTG and grown
for 5 h at 37 °C. The periplasmatic material was released
into buffer using an osmotic shock protocol [2]. Briefly,
cells were pelleted by centrifugation at 6,000 × g for
15 min. The pellet was resuspended in a 35 % sucrose
solution in 2 mM EDTA and 30 mM Tris–HCl (pH 7.2)
and incubated with shaking at room temperature for
15 min. The cells were again harvested and resuspended
in ice-cold water containing 5 mM MgSO4. The peri-
plasmatic material was boiled for 20 min and then cen-
trifuged for 30 min at 21,000 × g. 6His-alpha-synuclein
was purified from the supernatant by Ni-NTA affinity
chromatography using 20 mM sodium phosphate buffer,
pH 7.4, 500 mM NaCl, and 10 mM imidazole as binding
buffer and 20 mM sodium phosphate buffer (pH 7.4),
500 mM NaCl, and 500 mM imidazole as elution buffer on
an ÄKTA pure chromatography system (GE Healthcare).
The protein was dialyzed against 150 mM NaCl in 20 mM
Tris–HCl (pH 7.2), and used for seeding assays.
Thioflavin T binding assay
Kinetic seeding aggregation assays were performed by in-
cubating his-tagged monomeric alpha-synuclein (50 μM)
in low-binding black 96-well plates (Corning) at 37 °C in
TBS with 20 μM Thioflavin T (Sigma) and 0.05 % (w/v)
sodium azide (Sigma). Glass balls with 2 mm in diameter
(Hecht) were distributed into each well of the 96-well
plate to increase agitation. Seeds, 4 μl of a 10 % brain
homogenate, were sonicated for 15 min in in a TK-52
water bath sonifier (Bandelin) before adding to the sam-
ples. Fluorescence (440 nm excitation, 485 nm emission,
top read) was measured in an Envision multilabel reader
(Perkin Elmer) at 15 min intervals preceded by 45 s shak-
ing at 300 rpm in orbital mode with a 2 mm diameter.
Results
To investigate whether human wild-type alpha-synuclein
supports prion-like spreading of pathological alpha-
synuclein, we prepared and injected the sarkosyl-insoluble
fraction from cortical brain tissue from two patients with
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MSA, a 51-year-old female and a 59-year-old male, and
from two cases of probable iLBD, a 68-year-old female
and a 78-year-old male (Table 1), without clinical symp-
toms of parkinsonism or any other neurological disorder,
or phosphate-buffered saline (PBS) as a negative control
into the striatum of 6-8-week-old adult Tg(SNCA)1Nbm/J
mice (Table 2). Immunohistochemical analysis of brain
tissue sections of the two MSA and two probable iLBD
cases revealed that all patients displayed phosphorylated
alpha-synuclein in their brains, albeit in different cell types
and at different levels (Fig. 1a-e). Both MSA cases dis-
played prominent glial cytoplasmic inclusions that are
characteristic for MSA (Fig. 1a and b), whereas the inclu-
sions in both probable iLBD cases were neuronal as they
are observed in PD or DLB (Fig. 1c-e). Biochemical
analysis also revealed that these patient brains contained
detergent-insoluble phosphorylated alpha-synuclein spe-
cies that were absent in a control brain (Fig. 2 and
Additional file 2). We also observed a prominent
64 kDa band that was observable in the RIPA and
SDS fractions with the EP1536Y antibody against phosphor-
ylated alpha-synuclein and the Syn211 antibody against
alpha-synuclein.
Tg(SNCA)1Nbm/J mice are knockout for mouse
alpha-synuclein and homozygously express human wild-
type alpha-synuclein from an integrated P1 artificial
chromosome that contains the entire human SNCA
gene with its normal exon and intron structure as well
as 35 kb of upstream sequences [14, 21]. Brain protein
levels of human wild-type alpha-synuclein have been
reported to be only modestly elevated in these mice (1.3-
2.0-fold). Further analysis showed that the expression
and localization of alpha-synuclein in the brain is com-
parable between wild-type and Tg(SNCA)1Nbm/J mice
(Fig. 3). Moreover, these mice do not show overt alpha-
synuclein aggregation in brain or colon or any enteric
nervous system abnormalities. No detectable motor be-
havior impairments, autonomic abnormalities, olfactory
dysfunction, dopaminergic deficits, Lewy body pathology,
or neurodegeneration have been associated with human
alpha-synuclein expression in these mice. We monitored
these mice carefully for up to 9 months post injection.
Within this period none of the injected mice developed
visible signs of neurological disease.
We sacrificed Tg(SNCA)1Nbm/J mice at 3, 6, and
9 months post injection. Brain tissue sections of mice
injected with PBS did not show any staining for phos-
phorylated alpha-synuclein for up to 9 months post in-
jection (Fig. 5a). In contrast, brains of mice injected with
cortical extracts from MSA or probable iLBD cases ac-
cumulated abnormal intraneuronal inclusion bodies with
phosphorylated alpha-synuclein, which first became visible
at 6 months post injection (Figs. 4 and 5). At this time point
the pathological inclusion bodies containing phosphory-
lated alpha-synuclein were prominent in the ipsilateral
brain hemisphere and only few aggregates were observed in
the contralateral hemisphere (Fig. 4). No phosphorylated
alpha-synuclein had accumulated in rostral areas and only
very little in caudal areas. At 9 months post injection aggre-
gates with phosphorylated alpha-synuclein were more
abundant, equally present in both brain hemispheres, and
had spread to more rostral and caudal areas in the brain
(Figs. 4 and 5, and Additional file 3). The spatiotemporal
spread of synucleinopathy in the CNS was comparable
between all animals injected with MSA and iLBD brain
extracts for the observed time points (Table 2). Confocal
analysis showed that aggregates with phosphorylated alpha-
synuclein were indeed confined to neuronal cell bodies
(Fig. 5b). Only occasionally did phosphorylated alpha-
synuclein aggregates localize to astrocytes or microglia
(Additional file 4).
Staining for phosphorylated alpha-synuclein coloca-
lized with staining for alpha-synuclein only (Fig. 6a-l),
indicating that this antibody against phosphorylated
alpha-synuclein is targeting an epitope specific for a sub-
population of alpha-synuclein. While the 81A antibody
against phosphorylated alpha-synuclein may also non-
specifically recognize neurofilament light polypeptide
(also known as NF-L) [48], here staining for neurofila-
ment light polypeptide did not colocalize with that for
phosphorylated alpha-synuclein (Fig. 6m-x).
Further analysis of the intraneuronal inclusion bodies
with phosphorylated alpha-synuclein showed that these












4 30 μl PBS 3 No
4 30 μl PBS 6 No
4 30 μl PBS 9 No
4 30 μl MSA1 BE 3 No
4 30 μl MSA1 BE 6 Yes
4 30 μl MSA1 BE 9 Yes
4 30 μl MSA2 BE 3 No
4 30 μl MSA2 BE 6 Yes
4 30 μl MSA2 BE 9 Yes
4 30 μl iLBD1 BE 3 No
4 30 μl iLBD1 BE 6 Yes
4 30 μl iLBD1 BE 9 Yes
4 30 μl iLBD2 BE 3 No
4 30 μl iLBD2 BE 6 Yes
4 30 μl iLBD2 BE 9 Yes
PBS phosphate-buffered saline, BE brain extract, MSA multiple system atrophy,
iLBD incidental Lewy body disease
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aggregates additionally contained several proteins in-
volved in protein degradation. Staining for phosphory-
lated alpha-synuclein colocalized with that for ubiquitin
(Fig. 7a-l). Ubiquitin often labels pathological inclusions
that appear to be resistant to normal degradation includ-
ing alpha-synuclein in Lewy bodies and in glial and
neuronal cytoplasmic inclusions in MSA [23, 26, 52, 53].
In addition, staining for phosphorylated alpha-synuclein
also colocalized with that for sequestosome-1 (also known
as p62) (Fig. 7m-x and Additional file 5), which binds
to polyubiquitinated protein aggregates such as alpha-
synuclein in Lewy bodies [22]. Occasionally, few smaller
sized aggregates of sequestosome-1 could be detected that
did not colocalize with phosphorylated alpha-synuclein
(Additional file 5).
Next, we investigated whether Tg(SNCA)1Nbm/J mice
injected with cortical extracts from MSA or probable
iLBD cases or PBS had developed any form of gliosis in
their CNS at 9 months post injection. Staining with anti-
bodies against glial fibrillary acidic protein (GFAP) re-
vealed exclusively a mild reactive astrocytic gliosis in the
hippocampus of all mice but nowhere else in the CNS,
regardless if they had been injected with cortical extracts
from MSA or iLBD cases or PBS (Additional file 6). This
suggests that this transgenic mouse line has an intrinsic
property to develop mild hippocampal astrocytic gliosis
with age. Staining with antibodies against allograft in-
flammatory factor 1 (also known as Iba1) did not reveal
augmented activation of microglia in mice injected with
human brain extracts in comparison to mice injected
only with PBS (Additional file 7). Thus, the injections
did not cause any enhanced gliosis in Tg(SNCA)1Nbm/J
mice at 9 months post injection.
Consistent with the confocal imaging results, the bio-
chemical analysis showed phosphorylated alpha-synuclein
in the brains of mice injected with cortical extracts from
Fig. 1 Brains of MSA and probable iLBD cases contain pathogenic alpha-synuclein. Immunohistochemical staining with an antibody against
phosphorylated alpha-synuclein (81A) revealed glial cytoplasmic inclusions in cortical brain tissue sections from the MSA1 patient a and in
cerebellar brain tissue sections from the MSA2 patient b. Staining of cortical brain tissue sections with the same antibody also showed granular deposits
of phosphorylated alpha-synuclein in the cytoplasma and in neurites of cortical neurons from the iLBD1 c and iLBD2 cases d, e. Scale bar = 50 μm
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MSA and probable iLBD cases but not in mice injected
with PBS at 9 months post injection (Fig. 8). None of the
injected mouse brains contained detectable levels of phos-
phorylated alpha-synuclein species that were insoluble in
sarkosyl (Additional file 8) indicating that the intraneuro-
nal inclusion bodies, which had accumulated over time,
were not Lewy body-like but instead represented an early
stage synucleinopathy that might precede Lewy body
pathology.
To better identify the abnormal conformational change
of alpha-synuclein in the brains of mice injected with
brain extracts from patients with MSA and iLBD we per-
formed Thioflavin T (ThT) binding assays (Fig. 9). Our
results show that in contrast to brain homogenates from
mice injected with PBS those injected with brain extracts
from MSA and iLBD cases seeded aggregation of recom-
binant monomeric alpha-synuclein. This data further sup-
ports our histological findings that brain extracts from
Fig. 2 Biochemical analysis of alpha-synuclein in patient brains. Biochemical analysis of alpha-synuclein in patient brains shows that
SDS-extractable phosphorylated alpha-synuclein was only observed in samples from patient brains a but not in a control brain b. Sequentially
extracted fractions from brain homogenates of the MSA1, MSA2, iLBD1, and iLBD2 cases contain similar monomeric and oligomeric species of
alpha-synuclein when probed with the EP1536Y antibody against phosphorylated alpha-synuclein (upper panel) and with the Syn211 antibody
against alpha-synuclein (lower panel). Both antibodies recognize a prominent band at 64 kDa that may represent a tetramer (arrow) a and that is
absent in control brain b. Sequential extractions from a control brain did not reveal phosphorylated alpha-synuclein and only showed monomeric
alpha-synuclein in brain homogenate (BH), high salt (HS), and high salt-triton (HS-T) fractions (arrow) but not in the RIPA or SDS fraction b.
Molecular sizes are shown in kilodalton
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MSA and iLBD cases are able to induce templated mis-
folding and prion-like propagation of alpha-synuclein in
Tg(SNCA)Nmb1/J mice.
Discussion
In this study we have shown that intrastriatal injection
of cortical brain extracts from MSA and iLBD cases into
mice expressing human wild-type alpha-synuclein but
not endogenous mouse alpha-synuclein causes the appear-
ance and prion-like spreading of inclusion bodies that
contain phosphorylated alpha-synuclein in vivo. Prion-like
spreading of alpha-synuclein containing aggregates has
been shown in M83-mice overexpressing human alpha-
synuclein with the A53T-mutation and in wild-type mice
after injection with synthetic alpha-synuclein fibrils made
from recombinant protein [28, 29, 31]. Accumulation of
Fig. 3 Biochemical and histological analysis of alpha-synuclein expression in wild-type and Tg(SNCA)1Nbm/J mice. Biochemical analysis with an
antibody against alpha-synuclein (clone 42) that equally reacts with human as well as mouse alpha-synuclein shows that human alpha-synuclein
is only very moderately overexpressed in Tg(SNCA)1Nbm/J mice in comparison to alpha-synuclein expression in wild-type mice. Equal amounts
of total protein (5 μg) were loaded onto each lane of the SDS-polyacrylamide gel and show expression of alpha-synuclein in the striatum (Str),
cortex (Ctx), hippocampus (Hc), brainstem (Bs), and cerebellum (Cb). Molecular sizes are shown in kilodalton a. The signal for alpha-synuclein
was quantified by densitometry from western blots and normalized against tubulin and is shown as fold overexpression of alpha-synuclein in
Tg(SNCA)1Nbm/J mice (n = 3) versus wild-type mice (n = 3) b. Immunohistochemistry of mouse brain sections with the same antibody (clone 42)
against alpha-synuclein reveals comparable localization of alpha-synuclein in Tg(SNCA)1Nbm/J and wild-type mice c
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phosphorylated alpha-synuclein has also been shown after
inoculation of alpha-synuclein fibrils in M20-mice over-
expressing human alpha-synuclein in the presence of
endogenously expressed mouse alpha-synuclein [12, 46].
Recently, one study showed that brain homogenates from
MSA patients caused disease with incubation times of
143 ± 16 and 106 ± 11 days when injected in M83+/−-mice
[61]. However, injection of wild-type mice with brain ex-
tracts from patients with dementia with Lewy bodies only
led to deposits of alpha-synuclein in 50 % of the injected
mice at 15 months post injection that was mostly re-
stricted to the injected hemisphere [31]. Although human
and mouse alpha-synuclein can cross-seed each other, it is
possible that this inefficient transmission was due to a
species barrier as it is often observed in prion transmis-
sion studies where differences in the primary structure be-
tween the endogenously expressed prion protein and that
of the infectious prion protein in the inoculum can hamper
cross-species transmission [50]. Moreover, prion transmis-
sion studies to transgenic mice expressing the human
prion protein have shown that mice only became suscep-
tible to infection with human prions from Creutzfeldt-
Jakob patients when expression of the mouse prion protein
was ablated and only the human prion protein was
expressed [56, 57]. In this study, all Tg(SNCA)1Nbm/J
mice injected with patient brain extracts developed
synucleinopathy that efficiently spread to the contralateral
hemisphere within 9 months post injection suggesting that
sequence identity between the alpha-synuclein seeds from
human brain extracts and human wild-type alpha-
synuclein expressed in these mice and possibly also the
lack of endogenously expressed mouse alpha-synuclein
facilitated the prion-like spread. Interestingly, the lack of
endogenously expressed mouse alpha-synuclein did not
affect incubation times in M83+/−-mice after inoculation
with MSA brain homogenates [39]. Our qualitative ana-
lysis showed widespread localization of phosphorylated
alpha-synuclein in the CNS, including the cortex, of
Tg(SNCA)1Nbm/J mice after injection with patient brain
extracts. In spontaneously diseased M83-mice, there is
some accumulation of phosphorylated-alpha-synuclein in
the cortex but more in the cerebellum, brain stem, espe-
cially the mesencephalon, and spinal cord [12, 29]. The
distribution of alpha-synuclein pathology is however dif-
ferent in M83-, M20-, and wild-type mice that have been
injected with recombinant alpha-synuclein fibrils and in
these cases can more strongly involve the cortex [28, 48].
Differences in the localization of phosphorylated alpha-
synuclein may among other reasons arise from the type of
material injected, in our case patient brain extracts versus
recombinant fibrils of alpha-synuclein in the other mouse
models. While it is still a matter of investigation whether
Fig. 4 Prion-like spreading of phosphorylated alpha-synuclein. The diagram depicts areas in the brains of Tg(SNCA)1Nbm/J mice with inclusion
bodies that stained positive for phosphorylated alpha-synuclein at 6 and 9 months after intrastriatal injection with brain extracts from MSA or
probable iLBD cases into the left striatum (arrow). Staining for phosphorylated alpha-synuclein was verified with three different antibodies, 81A,
EP1536Y, and pSyn#64. Mice injected with PBS were devoid of staining for phosphorylated alpha-synuclein and inclusion bodies for up to
9 months post injection. In mice injected with brain extracts from MSA or probable iLBD cases inclusion bodies became first visible at 6 months
post injection and were more abundant in the left brain hemisphere where the injection had taken place. At 9 months post injection inclusion
bodies with staining for phosphorylated alpha-synuclein were more abundant and detectable to near equal amounts in both hemispheres and
had also spread to more rostral and caudal areas
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Fig. 5 (See legend on next page.)
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different strains of alpha-synuclein exist [36, 39], in prion
diseases, the pathology observed is dependent on the ex-
pression profile of the prion protein and the type of prion
strain inoculated [5]. In analogy, differences in the expres-
sion profile of alpha-synuclein could also affect the accu-
mulation pattern of alpha-synuclein pathology. Notably,
alpha-synuclein expression is driven in Tg(SNCA)1Nbm/J
mice from the human SNCA promoter and in M83- and
M20-mice from the hamster Prnp promoter.
Interestingly, punctate aggregates of phosphorylated
alpha-synuclein in the brains of Tg(SNCA)1Nbm/J mice
injected with brains extracts from patients with MSA or
iLBD colocalized with ubiquitin and p62 as has been ob-
served in earlier transmission studies to other mouse
models of synucleinopathies [31, 45–48]. In contrast to
another study in which wild-type mice were injected with
synthetic alpha-synuclein fibrils and accumulated dot-like
inclusions of phosphorylated microtubule-associated pro-
tein tau and TAR DNA-binding protein-43 (also known as
TDP-43), we did not observe accumulation of these pro-
teins in the brains of Tg(SNCA)1Nbm/J mice at 9 months
post injection of human brain extracts, which may reflect
differences of injected material [30].
In contrast to the mouse models described above
where alpha-synuclein pathology was first observed be-
tween 2 and 4 months post injection based on the model
and alpha-synuclein deposits were insoluble in detergent,
we detected alpha-synuclein pathology only at 6 months
post injection in our animal model. Moreover, in our
model the phosphorylated alpha-synuclein component in
the inclusion bodies was soluble in sarkosyl suggesting
that the inclusion bodies in injected Tg(SNCA)1Nbm/J
mice represent an early state of synucleinopathy. We
chose to terminate these experiments at 9 months post in-
jection and it is possible that a longer incubation time
after injection of MSA or iLBD brain extracts may have
resulted in more severe pathology with sarkosyl-insoluble
alpha-synuclein aggregates and clinical signs as observed
in M83+/−-mice injected with brain homogenate from
MSA patients [61] or wild-type mice injected with syn-
thetic alpha-synuclein fibrils [28, 31]. A recent study also
shows that intracerebral injections of 30 μl of a 1 % brain
homogenate from two MSA patients did not cause visible
signs of disease in Tg(SNCA)1Nbm/J mice within a year
[39]. Alternatively, expression levels of wild-type human
alpha-synuclein may be too low in Tg(SNCA)1Nbm/J
mice to allow for a more severe type of synucleinopathy to
develop. Cortical protein levels of the A53T-mutant of
human alpha-synuclein in M83+/−-mice are 3.3 ± 0.5-fold
and that of M20+/−-mice 5.6 ± 0.7-fold above that of
mouse alpha-synuclein expressed in wild-type mice [12].
Moreover, M83+/−- and M20+/−-mice still express en-
dogenous mouse alpha-synuclein, which could contribute
to the changes observed in those mice considering that
prion-like propagation of alpha-synuclein aggregates can
be induced in wild-type mice [28, 31]. Also, human wild-
type alpha-synuclein has a much lower propensity to ag-
gregate than human alpha-synuclein carrying the A53T
mutation, which is associated with familial PD, or than
murine wild-type alpha-synuclein, which naturally carries
threonine at this position [37, 44]. While this paper was in
preparation another study reported induction of alpha-
synuclein pathology in the brains of wild-type mice and
macaques after injection with Lewy body extracts from
brains of patients with PD [40]. Similar to our observations
Lewy body-injected mice and monkeys did not appear to
accumulate typical Lewy body-type aggregates but instead
showed phosphorylated alpha-synuclein that adopted a
more punctate, inclusion-like conformation. Importantly,
unlike brain homogenates from mice injected with PBS,
brain homogenates from mice injected with MSA and
iLBD patient brain extracts were able to seed alpha-
synuclein aggregation in vitro as determined by ThT bind-
ing assays, suggesting that these mouse brains contained
abnormal misfolded alpha-synuclein that was seeding com-
petent. Variation in the ThT fluorescence signal between
the different samples may be attributable to stochastic
sampling effects or possibly to a heterogeneous population
of abnormal alpha-synuclein species in the homogenates.
A limitation of ThT binding assay may be that it could de-
tect residual seeds originating form the injected patient
material. Considering that the histology results are negative
for phosphorylated alpha-synuclein at 3 months post injec-
tion and only become positive at 6 months post injection
for animals injected with patient brain extracts, this assay
likely detects de novo generated seeds.
In contrast to PD and DLB, where aggregates of alpha-
synuclein are mostly found in neurons, inclusions of
(See figure on previous page.)
Fig. 5 Accumulation of inclusion bodies in Tg(SNCA)1Nbm/J mice injected with brain extracts from MSA or probable iLBD cases. a Confocal
images show immunofluorescence staining with the 81A antibody for phosphorylated (S129) alpha-synuclein (red) at 9 months post injection
in brain sections of Tg(SNCA)1Nbm/J mice injected with brain extracts from MSA or probable iLBD cases or PBS. Neurons were stained with
an antibody against tubulin beta-3 chain (green) and nuclei with DAPI (blue). Staining for phosphorylated alpha-synuclein was absent in mice
injected with PBS. In contrast, mice injected with brain extracts from MSA or probable iLBD cases accumulated inclusion bodies with staining for
phosphorylated alpha-synuclein in many areas of the brain, including the cortex, striatum, hippocampus, brain stem, and cerebellum. b Confocal
images with orthogonal projections show that inclusion bodies with staining for phosphorylated alpha-synuclein (red) were located within
neuronal cell bodies. Scale bars = 10 μm
Bernis et al. Acta Neuropathologica Communications  (2015) 3:75 Page 11 of 18
misfolded alpha-synuclein in MSA have been mostly asso-
ciated with oligodendrocytes in the past. A recent study
however shows that in addition to glial inclusions also
neuronal inclusions of alpha-synuclein are widespread and
play an important role in the development and pro-
gression of MSA [6]. Interestingly, another study re-
ported that the structural conformation (strain) of the
injected alpha-synuclein aggregates, in this case fibrils
Fig. 6 Staining for phosphorylated alpha-synuclein is specific. Confocal imaging of brain sections of Tg(SNCA)1Nbm/J mice injected with brain
extracts from MSA or probable iLBD cases shows that at 9 months post injection staining with the EP1536Y antibody for phosphorylated (S129)
alpha-synuclein a-d and staining with the Syn211 antibody for human alpha-synuclein e-h colocalize when merged i-l. In contrast, staining with
the 81A antibody for phosphorylated alpha-synuclein m-p does not colocalize with staining for neurofilament light polypeptide q-t when merged
u-x. Nuclei were stained with DAPI (blue). Scale bar = 10 μm
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versus ribbons, was found to induce alpha-synuclein
inclusions only in neurons, as observed in PD, or in
neurons and oligodendrocytes, as observed for MSA
[36]. The latter, however, was observed only after
combined rAAV-mediated alpha-synuclein overexpres-
sion with alpha-synuclein ribbons inoculation, which
led to a second but sparse alpha-synuclein phosphor-
ylation in oligodendrocytes.
Fig. 7 Phosphorylated alpha-synuclein in inclusion bodies colocalizes with ubiquitin and sequestosome-1. Confocal imaging of brain sections of
Tg(SNCA)1Nbm/J mice injected with brain extracts from MSA or probable iLBD cases shows that at 9 months post injection staining with the
EP1536Y antibody for phosphorylated alpha-synuclein a-d and staining for ubiquitin e-h colocalize when merged i-l. In addition, staining with the
81A antibody for phosphorylated alpha-synuclein m-p colocalizes with staining for sequestosome-1 q-t when merged u-x. Nuclei were stained
with DAPI (blue). Scale bar = 10 μm
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In this study, brain extracts of MSA patients caused accu-
mulation of phosphorylated alpha-synuclein mostly in neu-
rons and rarely in oligodendrocytes of Tg(SNCA)1Nbm/J
mice. With regard to observations in M20-mice injected
with alpha-synuclein fibrils, we detected phosphorylated
alpha-synuclein aggregates only occasionally in astrocytes
and microglia (Additional file 4) [46], which may ex-
plain the lack of wide spread gliosis in our model system
(Additional files 6 and 7). A lack of oligodendroglial accu-
mulation of phosphorylated alpha-synuclein has also been
observed in M83+/−-mice injected with brain homogenates
from MSA patients and it was speculated that the lack of
alpha-synuclein aggregation in oligodendrocytes might be
due to poor transgene expression in these cells [39, 61].
Low expression levels of alpha-synuclein in oligodendro-
cytes may not support prion-like seeding and accumula-
tion of alpha-synuclein after transfer from neurons [43].
Expression of alpha-synuclein in M20- and M83-mice are
driven from the prion promoter, while expression of hu-
man alpha-synuclein in Tg(SNCA)1Nbm/J mice is driven
from a P1 artificial chromosome, which contains the
human promoter for alpha-synuclein. Although human
oligodendrocytes were long thought not to express alpha-
synuclein, a recent study revealed that the expression of
alpha-synuclein in MSA neurons and glial cells is en-
hanced [1, 32]. Thus, the lack of alpha-synuclein path-
ology in oligodendrocytes of Tg(SNCA)1Nbm/J mice
might be due to missing enhancer elements in the P1 arti-
ficial chromosome or to the lack of a yet unresolved
mechanism in trans, governing the expression of alpha-
synuclein in MSA. Our data does not argue for or against
the existence of strains with regard to misfolded alpha-
synuclein species and emphasize the necessity for add-
itional studies to understand this matter in greater detail.
ILBD is a prodromal form of synucleinopathy, e.g. PD
or DLB, that has not resulted in dementia or parkinson-
ism yet, and is found in 8-17 % of neurologically asymp-
tomatic individuals over the age of 60 on post-mortem
examination [7, 9, 10, 13, 16]. Cortical brain extracts
from the two probable iLBD cases investigated here
caused a similar spatiotemporally progressive synuclei-
nopathy in Tg(SNCA)1Nbm/J mice as those from the
two MSA patients, which lets us conclude that they were
indeed true iLBD cases. Moreover, several other trans-
mission studies to animal models in the past have shown
that a positive transmission result is not to be expected
in the absence of alpha-synuclein aggregates in the
injected material as it is observed after injection with PBS
[28, 29, 31, 47, 61]. The concentration of alpha-synuclein
in the sarkosyl-insoluble fraction of the iLBD2 sample was
slightly lower than in the other brain extracts (Table 1).
Titration experiments in prion transmission studies show
that only large differences in titers that can span several
tenfold dilutions lead to large differences in the incubation
time in inoculated animals [38, 54, 55]. We injected
Tg(SNCA)Nbm1/J mice with a high dose of misfolded
alpha-synuclein species from the sarkosyl-insoluble frac-
tion of MSA and iLBD brains and did not observe any
difference in the spatiotemporal expansion of alpha-
synuclein pathology in the brains of injected mice. Only
more comprehensive titration studies in mice with
sarkosyl-insoluble fractions from brain extracts of patients
with synucleinopathies will show at which concentrations
of alpha-synuclein differences in the spread of this path-
ology becomes observable. Our findings argue that the
pathologic alpha-synuclein species in the brains of patients
with iLBD are comparable to those from MSA brains in
their ability to induce pathology in Tg(SNCA)1Nbm/J
mice.
Conclusions
We show that human wild-type alpha-synuclein by
itself, in the absence of endogenously expressed mouse
alpha-synuclein, supports a prion-like mechanism in the
Fig. 8 Brains of mice injected with brain extracts from MSA and
probable iLBD cases but not PBS accumulate phosphorylated
alpha-synuclein. Brains of Tg(SNCA)1Nbm/J mice injected with brain
extracts from MSA or probable iLBD cases or PBS were biochemically
analyzed at 9 months post injection with antibodies against
alpha-synuclein (Syn211) or phosphorylated alpha-synuclein (81A).
All mouse brains contained equal amounts of sarkosyl-soluble
alpha-synuclein (upper panel). Phosphorylated alpha-synuclein,
however, was not detectable in mouse brains injected with PBS but
in mouse brains injected with brain extracts from MSA or probable
iLBD cases (lower panel). Detection of tubulin beta chain shows
equal loading in all lanes. Molecular sizes are shown in kilodalton
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spreading of pathological alpha-synuclein, which does
not necessitate the presence of fulminant Lewy body-
type pathology. In our experiments sarkosyl-soluble
pathogenic alpha-synuclein species, which need to be
further characterized, were readily transmitted between
neurons supporting the concept that the appearance of
additional detergent-insoluble alpha-synuclein species
and Lewy body pathology may represent a late cellular
Fig. 9 Thioflavin T binding assay detects abnormal alpha-synuclein in the brains of mice injected with brain extracts from MSA and iLBD patients.
Shown is the time dependent increase in Thioflavin T (ThT) fluorescence measured in relative fluorescence units (RFU) over a period of 72 h. Brain
homogenates from mice injected with PBS did not seed aggregation of alpha-synuclein, suggesting that they did not contain abnormal alpha-synuclein.
In contrast, brain homogenates from mice injected with brain extracts from patients with MSA1, MSA2, iLBD1, and iLBD2 lead to an increase in ThT
fluorescence over time, suggesting that the brains of these mice contained abnormal alpha-synuclein that was seeding competent. Each row represents
replicates from the same whole brain homogenate of mice collected at 9 months post injection
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event in mature synucleinopathies [19, 34, 41]. Conse-
quentially, potential therapeutic strategies targeting the
interneuronal spread of soluble pathogenic alpha-synuclein
in synucleinopathies such as PD or MSA may be promising
but effective only early in the disease process.
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